Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLN12140 in complement inhibitor-naïve PNH
NCT07387302Phase 2Not yet recruiting
- Sponsor
- Linno Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Nanobodies (VHH)
01
Overview
A Phase 2 trial of SLN12140 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Linno Pharmaceuticals. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
SLN12140
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT07387302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07387302.